The company anticipates a significant negative impact on sales of its second-largest product, STELARA, as biosimilar versions launch globally. This creates intense pressure to offset revenue loss, optimize commercial operations, and reduce costs.
Filing excerpt
The Company expects continued launches of biosimilar versions of STELARA globally which will continue to negatively impact the Company’s sales of STELARA.
What this signalsFilings often name leadership changes, deals and spending plans.
Competitors
Regions named
sec-10kcompetitorNamedGet every 10-K signal for Johnson & Johnson and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/0a91e65a-13d0-42fc-9ab2-9956910d586e returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.
{
"signal_id": "0a91e65a-13d0-42fc-9ab2-9956910d586e",
"signal_type": "sec-10k",
"signal_subtype": "competitorNamed",
"detected_at": "2026-02-17T06:28:56.417+00:00",
"company": {
"name": "Johnson & Johnson",
"domain": "jnj.com"
},
"data": {
"detail": "The company anticipates a significant negative impact on sales of its second-largest product, STELARA, as biosimilar versions launch globally. This creates intense pressure to offset revenue loss, optimize commercial operations, and reduce costs.",
"metrics": {
"pct": 0.065,
"timeframe": "current_year",
"pct_context": "percentage of total fiscal 2025 revenue from STELARA"
},
"summary": "J&J faces revenue loss for STELARA (6.5% of total revenue) due to biosimilar competition.",
"excerpts": "The Company expects continued launches of biosimilar versions of STELARA globally which will continue to negatively impact the Company’s sales of STELARA.",
"relevance": 0.85,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/28",
"sales_relevance": "Competitive intelligence",
"signal_category": "market",
"regions_mentioned": [
"U.S.",
"Europe"
],
"competitors_mentioned": [
"biosimilar manufacturers"
]
}
}
curl https://signals.autobound.ai/v1/signals/0a91e65a-13d0-42fc-9ab2-9956910d586e \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.